This site is intended for healthcare professionals

Auris Medical provides update on Bentrio program in allergy.

Read time: 2 mins
Last updated:8th May 2021
Published:9th May 2021
Auris Medical Holding Ltd. a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, and its affiliate Altamira Medica Ltd. announced additional details on the outcomes from the clinical investigation of its Bentrio (formerly AM 301) nasal spray in allergic rhinitis and provided an update on the regulatory pathway in the US for the intended use in allergy.
Condition: Allergy / Grass
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest